Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44] (Leukemia Research (2019) 79 (38–44), (S0145212619300384), (10.1016/j.leukres.2019.02.012)) Article uri icon

Overview

MeSH Major

  • Apoptosis
  • Erythroid Precursor Cells
  • Ikaros Transcription Factor
  • Up-Regulation

abstract

  • © 2019 Elsevier Ltd The authors regret that there is an error in the email address of the corresponding author. Dr. Gerds' correct email address is gerdsa@ccf.org. The authors would like to apologise for any inconvenience caused.

publication date

  • January 2019

Research

keywords

  • Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2019.04.006